Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. in vivo: Mean change
ROS 234 is a highly effective H3antagonist, demonstrating a strong binding affinity (pK B) of 9.46 for the Guinea-pig ileum H3receptor and a pKi of 8.90 for the Rat cerebral cortex H3receptor. Additionally, it exhibits an ex vivo ED50 of 19.12 mg kg (ip) in the Rat cerebral cortex. It should be noted that ROS 234 demonstrates limited central access, as reported in [1] and [2].
H3R antagonist 2 (Compound 23) is a multitarget histamine H3receptorantagonist. It exhibits inhibitory effects on acetylcholinesterase, butyrylcholinesterase, and human monoamine oxidase B (hMAO B) with IC50 values of 180 nM, 880 nM, and 775 nM, respectively. With a Ki of 170 nM for hH3R, H3R antagonist 2 demonstrates favorable anti-neuropathic pain and memory-enhancing effects. Additionally, it can cross the blood-brain barrier (BBB) [1].